US Patent 9981930 MAGL inhibitors
Patent 9981930 was granted and assigned to Abide Therapeutics on May, 2018 by the United States Patent and Trademark Office.
All edits
Edits on 27 Jun, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+278 characters)
Article
Patent abstract
Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09981930 MAGL inhibitors US Patent 9981930 MAGL inhibitors
Infobox
Patent Number
0998193000
Patent Number
998193000
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
099819300
Date of Patent
May 29, 2018
0Patent Application Number
158143180
Date Filed
November 15, 2017
0Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
099819300
Date of Patent
May 29, 2018
0Patent Application Number
158143180
Date Filed
November 15, 2017
0Patent Primary Examiner
Edits on 20 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 09981930 MAGL inhibitors
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
09981930
Date of patent
May 29, 2018
Patent application number
15814318
Date Filed
November 15, 2017
Patent primary examiner
Find more entities like US Patent 9981930 MAGL inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
